¸ð½Ã´Â±Û ÇÁ·Î±×·¥ ÃÊ·ÏÁ¢¼ö »çÀüµî·Ï ¹ßÇ¥ÀÚ ¾È³» ¼ö»óÀÚ ¾È³» Çà»çÀå¾È³» ¼÷¹Ú¾È³» Ȩ
 ÀϹݿ¬Á¦ ¹ßÇ¥ À¯ÀÇ»çÇ×

ÀϹݿ¬Á¦ ¹ßÇ¥ÀÚ´Â ¹Ýµå½Ã ¹ßÇ¥ ½½¶óÀ̵å(ÆÄ¿öÆ÷ÀÎÆ®)¸¦ »çÀü¿¡ Á¦ÃâÇÏ¼Å¾ß ¹ßÇ¥°¡ °¡´ÉÇÕ´Ï´Ù.
½½¶óÀ̵带 ±âÇÑ ³»¿¡ Á¦ÃâÇÏÁö ¾ÊÀ» °æ¿ì¿¡´Â ¹ßÇ¥ºÒ°¡´ÉÀ¸·Î °£ÁÖÇÕ´Ï´Ù.
¹ßÇ¥ ½½¶óÀ̵å¼ö´Â 15¸Å À̳»·Î 1Àå ´ç 10ÁÙ À̳»·Î Á¦ÀÛÇϽô °ÍÀ» ±ÇÀåÇϸç, ÁöÁ¤µÈ ¹ßÇ¥½Ã°£(7ºÐ ¹ßÇ¥-3ºÐ ÁúÀÇÀÀ´ä)À» Á¤È®È÷
ÁöÄÑÁֽñ⠹ٶø´Ï´Ù.


1. ÆÄÀÏ Á¦Ã⸶°¨ÀÏ : 9¿ù 22ÀÏ(¿ù)
2. ÆÄÀÏ ÇüÅ : ÆÄ¿öÆ÷ÀÎÆ®
3. Á¦Ãâ ¹æ¹ý : office@ksog.org
¸ðüžÆÀÇÇР  /    »ý½Ä³»ºÐºñÇР  /    ºÎÀÎÁ¾¾çÇР  /    ÀϹݺÎÀΰúÇÐ
ÀϹݿ¬Á¦ : ºÎÀÎÁ¾¾çÇÐ - ÀϽà : 2014³â 9¿ù 26ÀÏ (±Ý)
- Àå¼Ò : ¿¡¸Þ¶öµåȦ B[3F]
GO1-GO4 (08:20~09:00) ÁÂÀå : ·ù±â¼º(°¡Å縯ÀÇ´ë)
GO108:20~08:30 ³²ÀºÁö
¿¬¼¼´ëÇб³ ¼¼ºê¶õ½ºº´¿ø »êºÎÀΰú
Pancreatic adenocarcinoma up-regulated factor (PAUF) expression in ovarian mucinous adenocarcinoma associated with a poor prognosis
GO208:30~08:40 ¾ç¼±¿µ
°í·ÁÀÇ´ë ±¸·Îº´¿ø »êºÎÀΰú
ASC-US and LSIL triage in Korean women: Revisiting the 2012 ASCCP screening guidelines
GO308:40~08:50 ±èÁ¤Àº
°Ç±¹´ëÇб³º´¿ø »êºÎÀΰú
Prediction model for 30-day morbidity after gynecological malignancy surgery
GO408:50~09:00 ÇãÀºÁø
¼º±Õ°üÀÇ´ë »ï¼º¼­¿ïº´¿ø »êºÎÀΰú
The impact of the interval from surgery to initiation of chemotherapy (ISC) on survival in advanced epithelial ovarian cancer
GO5-GO8 (09:00~09:40) ÁÂÀå : ±èÀçÈÆ(¿¬¼¼ÀÇ´ë)
GO509:00~09:10 ¹èÈ¿¼÷
±¹¸³¾Ï¼¾ÅÍ
Predictive factor and risk group analysis for the local recurrence/persistent disease in cervical cancer patients who underwent primary concurrent chemoradiotherapy (CCRT)
GO609:10~09:20 ¹éÀ̼±
¼º±Õ°üÀÇ´ë »ï¼º¼­¿ïº´¿ø »êºÎÀΰú
Laparoscopic surgical management of localized recurrent ovarin cancer
GO709:20~09:30 ÀÓ¸íö
±¹¸³¾Ï¼¾ÅÍ
A simple new technique of diaphragmatic peritonectomy: hand-pushing down with anchoring both ends
GO809:30~09:40 ÀÌÁ¤¿ø
¼º±Õ°üÀÇ´ë »ï¼º¼­¿ïº´¿ø »êºÎÀΰú
Anti-angiogenic Effect of Itraconazole in Epithelial Ovarian Cancer
GO9-GO12 (09:40~10:20) ÁÂÀå : ³²°èÇö(¼øõÇâÀÇ´ë)
GO909:40~09:50 ¼­µ¿ÈÆ
¼­¿ï´ëÇб³ ºÐ´çº´¿ø »êºÎÀΰú
Survival impact of surgical spillage in stage I clear cell carcinoma of ovary: Korean multicenter study.
GO1009:50~10:00 Á¤ÇʽÂ
¿ï»êÀÇ´ë ¼­¿ï¾Æ»êº´¿ø »êºÎÀΰú
Poor prognosis after conservative surgery in stage I mucinous epithelial ovarian cancer
GO1110:00~10:10 ÀÌÁ¤À±
¼­¿ï´ëÇб³º´¿ø »êºÎÀΰú
A low-risk group for parametrial involvement is accurately identified by criteria used in ongoing studies and new criteria using MRI in microscopic stage IB1 cervical cancer
GO1210:10~10:20 ÀÓ¸íö
±¹¸³¾Ï¼¾ÅÍ
Colon cancer as a second primary cancer after endometrial cancer based on shared etiology: a proof of concept study
GO13-GO16 (11:00~11:40) ÁÂÀå : ¹®Çý¼º(ÀÌÈ­ÀÇ´ë)
GO1311:00~11:10 ±â°æµµ
°­µ¿°æÈñ´ëÇб³º´¿ø »êºÎÀΰú
XAF1 is activated by TNF¥á and mediated TNF¥á-induced apoptosis in ovarian cancer cells
GO1411:10~11:20 ÀÓ°¡¿ø
¿¬¼¼´ëÇб³ ¼¼ºê¶õ½ºº´¿ø »êºÎÀΰú
Long non-coding RNA HOXA11as is associated with survival in advanced epithelial ovarian cancer
GO1511:20~11:30 ±¸À¯Áø
°í·ÁÀÇ´ë ±¸·Îº´¿ø »êºÎÀΰú
Discordance of histopathologic diagnosis between colposcopy-guided biopsy and conization in high-grade cervical intraepithelial lesions
GO1611:30~11:40 Á¤ÇʽÂ
¿ï»êÀÇ´ë ¼­¿ï¾Æ»êº´¿ø »êºÎÀΰú
Diagnostic value of combined 18F-FDG positron emission tomography/computed tomography in recurrent epithelial ovarian cancer with non-disseminated lesions
GO17-GO20 (11:40~12:20) ÁÂÀå : À̼±°æ(°æÈñÀÇ´ë)
GO1711:40~11:50 ÀÌÁöÀ±
¿¬¼¼ÀÇ´ë °­³²¼¼ºê¶õ½ºº´¿ø »êºÎÀΰú
Makorin Ring Finger Protein 1 (MKRN1) as an adjunct marker in liquid-based cervical cytology
GO1811:50~12:00 ÀÌÁö¼±
¾ÆÁÖ´ëÇб³º´¿ø »êºÎÀΰú
Predicting model for lymph node metastasis using preoperative tumor grade, transvaginal ultrasound, and serum CA-125 level in patients with endometrial cancer
GO1912:00~12:10 ·ù±âÁø
°í·ÁÀÇ´ë ¾È¾Ïº´¿ø »êºÎÀΰú
Clinical Significance of HPV DNA Co-testing in Korean Women with atypical squamous cells-cannot exclude high-grade squamous intraepithelial lesion (ASC-H).
GO2012:10~12:20 ÀÌÁö¿µ
Ä¥°î°æºÏ´ëÇб³º´¿ø »êºÎÀΰú
Cytokeratin 19 and human papilloma virus in lymph node of cervical cancer patients with intermediate risk factors
GO21-GO24 (12:20~13:00) ÁÂÀå : À̱âÇå(°üµ¿ÀÇ´ë)
GO2112:20~12:30 ½Å¼ÒÁø
°è¸íÀÇ´ë µ¿»êÀÇ·á¿ø »êºÎÀΰú
The Hsp90 Inhibitor SY-016, Induces G2/M Arrest and Apoptosis in Paclitaxel-resistant Human Ovarian Cancer Cells
GO2212:30~12:40 À̹ξÆ
ÀÌÈ­¿©ÀÚ´ëÇб³ ÀÇ°ú´ëÇÐºÎ¼Ó ¸ñµ¿º´¿ø »êºÎÀΰú
Synergistic effect of HPV E6/E7 siRNA in combination with Cisplatin on Basal dynamic studies of TP53
GO2312:40~12:50 ¼Õ±Ý¼±
¿¬¼¼ÀÇ´ë °­³²¼¼ºê¶õ½ºº´¿ø »êºÎÀΰú
Chemosensitivity testing based on gene expression profiling in patients with ovarian cancer
GO2412:50~13:00 ±èÇüÁÖ
¿¬¼¼ÀÇ´ë °­³²¼¼ºê¶õ½ºº´¿ø »êºÎÀΰú
Forkhead box P1 (Foxp1) in cervical cancer
GO25-GO28 (14:00~14:40) ÁÂÀå : °í¼®ºÀ(´ë±¸°¡Å縯ÀÇ´ë)
GO2514:00~14:10 ±èÁ¤Áø
¼º±Õ°üÀÇ´ë °­ºÏ»ï¼ºº´¿ø »êºÎÀΰú
Comparison of barbed suture versus traditional suture in laparoendoscopic single-site myomectomy
GO2614:10~14:20 ¼ÕÁÖÇõ
¾ÆÁÖ´ëÇб³º´¿ø »êºÎÀΰú
Cutoff value of pre- and post-cone HR-HPV load predicting residual/recurrent disease after conization in high-grade intraepithelial neoplasia and microinvasive carcinoma of the uterine cervix
GO2714:20~14:30 À̽ÂÁ¤
°æºÏ´ëÇб³º´¿ø »êºÎÀΰú
Single-port nerve sparing laparoscopic radical hysterectomy with extended node dissection for cervical cancer
GO2814:30~14:40 ¹èÀ縸
ÇѾç´ëÇб³º´¿ø »êºÎÀΰú
Laparoscopic Cytoreductive Surgery in Women with Epithelial Ovarian Cancer
GO29-GO33 (14:40~15:30) ÁÂÀå : ÇѼ¼ÁØ(Á¶¼±ÀÇ´ë)
GO2914:40~14:50 ±èÁöÈñ
¼­¿ï´ëÇб³º´¿ø »êºÎÀΰú
Detecting asymptomatic recurrence in early stage endometrial cancer- the value of vaginal cytology, imaging studies and CA-125
GO3014:50~15:00 ±è¿¬¼±
°í·ÁÀÇ´ë ±¸·Îº´¿ø »êºÎÀΰú
Clinical impact of the number of the retrieved pelvic lymph nodes in epithelial ovarian cancer
GO3115:00~15:10 ±èÈñÁ¤
¿¬¼¼´ëÇб³ ¼¼ºê¶õ½ºº´¿ø »êºÎÀΰú
Steroid Receptor Activator induces tumor proliferation and invasion through the Notch pathway in the human ovarian cancer
GO3215:10~15:20 ¼­µ¿¼ö
ºÎ»ê´ëÇб³º´¿ø »êºÎÀΰú
DDX4 (DEAD box polypeptide 4) colocalizes with cancer stem cell marker CD133 in ovarian cancers
GO3315:20~15:30 ÀÌ´Ù¿ë
¼­¿ï´ëÇб³º´¿ø »êºÎÀΰú
Prognosis and Associated Factors in Neuroendocrine Cervical Carcinoma (NECC)